Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 2.5 mg, 5 mg, 10 mg) |
Drug Class | Soluble guanylate cyclase stimulators |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Latest News
Summary
- Verquvo (vericiguat) is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or the need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
- This summary is based on the review of seven systematic review(s)/meta-analysis(es). [1-7]
- Vericiguat reduced the risk of cardiovascular death and heart failure (HF) hospitalization in patients with reduced ejection fraction (HFrEF) but showed no significant effect in patients with preserved ejection fraction (HFpEF).
- The primary endpoint, a composite of cardiovascular mortality and first HF-related hospitalization, was significantly reduced by vericiguat, particularly in chronic heart failure patients, with no significant impact on all-cause or cardiovascular mortality.
- Vericiguat's effectiveness was consistent irrespective of atrial fibrillation status and in patients with NT-proBNP levels up to 8000 pg/ml, demonstrating a reduction in both cardiovascular death and HF hospitalizations.
- General Safety Profile: Vericiguat demonstrated a favorable safety profile, with no significant difference in adverse effects compared to placebo. Notable adverse events included hypotension, syncope, and anemia, but these were not statistically significant.
- Significant Safety Concerns: There was a potential, but not statistically significant, increase in the risk of symptomatic hypotension and syncope, particularly in patients with reduced ejection fraction.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Verquvo (vericiguat) Prescribing Information. | 2023 | Merck Sharp and Dohme Corp., Rahway, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and safety of vericiguat for treatment of heart failure: a systematic review. | 2023 | Current Problems in Cardiology |
Efficacy and safety of vericiguat in heart failure: a meta-analysis. | 2023 | Journal of International Medical Research |
A systematic review of the effect of vericiguat on patients with heart failure. | 2023 | International Journal of Molecular Sciences |
The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials. | 2023 | Medicine |
Vericiguat treatment of heart failure: a systematic review and meta-analysis. | 2023 | World Journal of Clinical Cases |
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. | 2022 | Basic & Clinical Pharmacology & Toxicology |
Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis. | 2020 | World Journal of Cardiology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Diagnosis and management of heart failure from hospital admission to discharge: a practical expert guidance. | 2022 | Annales de Cardiologie et d'Angéiologie |